Uptake of L-methyl-"C-methionine ("C-methionine) in breast cancer metastases was studied with positron emission tomography (PET). Eight patients with soft tissue metastases were studied twice: before ! the onset of chemotherapy (4), hormonal therapy (3) or radiotherapy (1) 
In oncology the evaluation of treatment response to cancer therapy is a fundamental issue and is usually aided by radiological or nuclear imaging. Positron emission tomography (PET) has opened a totally new approach in evaluating metabolical changes in cancer tissue caused by chemotherapy or radiotherapy in vivo. Using a glucose analogue '8F-2-fluoro-2-deoxy-D-glucose (FDG) and PET imaging may be a valuable method in predicting treatment response in head and neck cancer (Minn et al., 1988) , breast cancer (Minn & Soini, 1989) and lung cancer (Abe et al., 1990) . Active metabolism may be visualised by radiotracers such as FDG or L-methyl-"C-methionine ("C-methionine) which take part in altered turnover of glucose or amino acids in cancer tissue (Kubota et al., 1985; Wahl et al., 1991) .
Methionine is necessary in cancer cells for increased protein and polyamine synthesis and in transmethylation reactions. This essential amino acid has a central role in the altered metabolism of malignant cells (Hoffman, 1990) . The amino acid metabolism of cancer tissue can be studied in vivo by measuring uptake of "C-methionine by PET. The uptake has been reported to decrease rapidly as a response to radiation therapy in an experimental tumour model and to bromocriptine treatment in pituitary adenomas (Bergstrom et al., 1987) .
We studied the uptake of "C-methionine in breast cancer metastases to find out whether the change in the uptake during cancer therapy could predict the clinical response to treatment. (Table I ).
Materials and methods

Patients
The size of the metastases was recorded at the time of the first PET study, the time of the second PET study and finally 3-6 months after the beginning of the therapy, at which time the clinical response was evaluated according to the criteria of WHO (Miller et al., 1981 (Spinks et al., 1988) . "C-methionine was synthesised at Turku University Radiochemistry Laboratory as described elsewhere (Langstr6m et al., 1987) . The purity of "C-methionine was higher than 92,5%, except in two studies, where it was 82.0% (study I of patient 6) and 89,0% (study II of patient 8). The remaining radioactivity was mainly in the form of "C-methionine sulphoxide as discussed elsewhere (Nagren, 1992 of the clavicular region and a 20-25 min scan for the trunk. "C-methionine (160-320 MBq) was injected into an upper extremity vein. After the injection, the dynamic emission scanning was carried out for 60 min the frame times being 4 x 30s, 3 x 60s, 5 x 180s, 4 x 300s and 2 x 60s.
Blood sampling
Frequent venous blood samples were taken during the emission scanning from a cubital vein contralateral to the injection site. A total of 17 blood samples were taken, ten of which during the first 3 min after the injection. To ease the blood sampling the arm was first heated with a pad. The radioactivity concentration of the plasma samples was determined. The low molecular weight fraction of plasma samples, which consists mainly of "C-methionine, taken at 10, 20, 40
and 60 min after the injection was separated by fast gel filtration (Sephadex PD-10 columns, Pharmacia Fine Chemicals, Sweden) and the radioactivity concentration was determined for curve fitting.
ROI analysis
One or more regions of interest (ROIs) in two to three planes were drawn on the hot spots in the tumour. The size of the ROIs was restricted to the highest accumulation area and was always smaller than the total tumour area. The ROI with the maximum average counts in the frame representing the time between 35 and 40 min of the dynamic study was selected to represent the 11C-methionine uptake in the tumour in the analysis of the standardised uptake value (SUV). The respective time activity curve was used in the kinetical analysis.
Kinetical analysis A graphical approach according to Patlak was used to analyse the irreversible "C-methionine uptake in the tumour tissue (Patlak et al., 1983 
Results
The soft tissue metastases of all the eight breast cancer patients were clearly visualised with "C-methionine ( Figure  1 ). The uptake of "C-methionine was rapid and achieved a plateau in 10 to 15 min (Figure 2 ). When the radioactivity concentration of the low molecular weight fraction of plasma was used as an input function in the graphical analysis according to Patlak, a straight line was obtained in the plot at 11 min after injection. The line was straight in all studies from 25 to 40 min, and the influx constant was calculated of seven to ten data points of this period (Figure 3) . A partial remission was seen in three cases (Table IT) . The
Ki decreased in two of these cases (a decrease of 48% and of 15%) and remained the same in the remaining case (a decrease of 2%). Of the five cases with progressive disease, the Ki increased in four (an increase of 12%, 15%, 19% and 68%) and decreased slightly in one metastasis (a decrease of 5%) (Table II) . The SUVs of all metastases that responded to the therapy decreased, increased in three and remained the same in two of the five metastases that progressed during treatment (Table III) . The greatest difference between the two uptake values was observed in a responding pulmonary metastasis that was studied after a 13 week interval (patient 3).
The uptake rate (Ki) before the start of the new therapeutic modality ranged from 0.035 to 0.186 min-' and the SUV from 2.5 to 11.4, respectively. The Ki measured during the therapy ranged between 0.030 and 0.143 min-' and the SUV between 2.0 and 7.8. The highest uptake of "C-methionine was measured in a pulmonary metastasis, where the Ki was 0.186 min-' and the SUV 11.4 (patient 3). This patient experienced a long lasting, strong partial response to tamoxifen treatment, and she is surviving after 2 years of the PET studies. No correlation was obtained between the number of previous therapeutic intentions, or rapidity of progression of the disease, and the uptake rate of "C-methionine.
There was a good correlation between the Ki and SUV in this series (r = 0.86, P <0.0001, n = 16) (Figure 4 ). Figure 4 Correlation between the input corrected uptake rate of "C-methionine K, and the standardised uptake value SUV.
Discussion
In our study, all breast cancer soft tissue metastases had a clear uptake of "C-methionine. In three of the five progressing metastases the uptake values increased and remained the same in two, and decreased in all the three regressing metastases.
In one of the cases (patient 7, (Nicholson, 1989) ). The uptake of '"C-methionine may be associated with the malignancy grade of these tumours (Leskinen-Kallio et al., 1991 a and 1992b) .
The graphical analysis method according to Patlak (Patlak et al., 1983 ) has been applied to "C-methionine PET tumour studies by Bergstrom et al. (1986) , Hatazawa et al. (1989) and ourselves (Leskinen-Kallio et al., 1991a) . As an input function we used the radioactivity concentration of the low molecular weight fraction of plasma, which consists mainly of "C-methionine and not its metabolites (Lundqvist et al., 1985) . A straight line was obtained in the plot during 11 to 40min of the study. This represents the irreversible uptake "C-methionine from plasma to the cancer tissue. This method requires 40 min emission scanning time, several blood samples, and the separation of the low molecular weight fraction of the plasma by fast gel filtration or measuring the "C-methionine concentration by high pressure liquid cromatography. In this material, there was an excellent correlation between the SUVs and Kis. For SUV analysis, only 5 to 10 min emission scanning time is needed 20 to 30 min after injection. SUV analysis seems to be an adequate method for clinical PET studies with "C-methionine in breast cancer (Leskinen-Kallio et al., 1992a) .
In measuring the accumulation of "C-methionine in the tumour several factors may affect the ultimate count detected. The differences in the tumour blood flow (Abe et al., 1990) , physiological circumstances such as the body temperature, the location of the tumour in the field and the complex metabolism of methionine (Hoffman, 1984) should be beared in mind when interpreting the results of PET studies. The error marginal in PET studies is approximately 5% (Spinks et al., 1988) . Minimising these errors and providing the quality and reproducibility of PET studies needs strict standardisation of the study protocol and regular normalisation and calibration of the scanner. Breast cancer metastases even with the diameter of 2 cm can be imaged with "C-methionine and PET. An increase in the uptake of "C-methionine 6 to 7 weeks after the beginning of anticancer therapy may predict poor response. Further studies with a larger patient material are needed. Different scanning intervals need to be tested to get more information about changes in amino acid metabolism in breast cancer metastases, and the value of PET in evaluating the treatment response.
